With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1120-95-2,3-Chloropyridazine,as a common compound, the synthetic route is as follows.
Intermediate 23; Ethyl (trans^-oxo-S-O-pyridazinvD-i-oxa-S-azaspiroK.deltaidecane-delta-carboxylatet; Ethyl (trans)-2-oxo-1-oxa-3-azaspiro[4.5]decane-8-carboxylate (prepared in an analogous fashion to Intermediate 15, 250 mg, 1.100 mmol), 3-chloropyridazine (for a preparation see WO2001007416, 126 mg, 1.100 mmol), trans-1 ,2-diaminocyclohexane (0.066 ml, 0.550 mmol), copper(l) iodide (105 mg, 0.550 mmol), K3PO4 (1168 mg, 5.50 mmol) were collected and shaken at 120 0C for 8 h. Solvent was removed under vacuum, rinsed with DCM (10 ml) and filtered over a separation tube. The resulting solution was then purified with Biotage SP1 , over a Silica 25M column, eluting with a gradient of DCM and Et2O. The title compound was eluted with ca 15% Et2O and recovered as a colourless solid (1 10 mg).
The synthetic route of 1120-95-2 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; GLAXO GROUP LIMITED; WO2008/92887; (2008); A1;,
Pyridazine – Wikipedia
Pyridazine | C4H4N2 – PubChem